Gilead looks towards NASH combo data after selonsertib fails in second Phase III
Gilead's selonsertib has failed in another Phase III NASH trial, this time missing the primary endpoint in patients with a less severe stage of fibrosis. The company will focus on its combination strategy to treat non-alcoholic steatohepatitis (NASH).
Gilead Sciences Inc. (NASDAQ:GILD) said Thursday that selonsertib (GS-4997) missed the primary endpoint of at least a one-stage histologic improvement in fibrosis without worsening of NASH at 48 weeks vs. placebo in the Phase III STELLAR-3 trial to treat patients with bridging fibrosis (F3) due to NASH. In February, the company said selonsertib missed the same primary endpoint in the Phase III STELLAR-4 trial in compensated cirrhosis (F4) due to NASH, which is a more severe form of fibrosis than F3 (see "Gilead’s selonsertib fails Phase III for NASH compensated cirrhosis"). ...